The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer

Canadian Urological Association Journal

Volumn 11, Issue 6, 2017, Pages 167-171

  Nayan, Madhur ^a   Hamilton, Robert J ^a   Finelli, Antonio ^a   Austin, Peter C ^b,c   Kulkarni, Girish S ^a   Juurlink, David N ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; DRUG USE; FEMALE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OBESITY; OVERALL SURVIVAL; SCORING SYSTEM; SMOKING; STATISTICAL MODEL; SURVIVAL TIME;

EID: 85020765593     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.4569     Document Type: Article

References (33)

1. Thygesen LC, Ersbøll AK. When the entire population is the sample: Strengths and limitations in registerbased epidemiology. Eur J Epidemiol 2014;29:551-8. https://doi. org/10. 1007/s10654-013-9873-0
2. Jeon CY, Pandol SJ, Wu B, et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: A SEER-Medicare analysis. PLoS One 2015;10:e0121783. https://doi. org/10. 1371/journal. pone. 0121783
3. Nayan M, Macdonald EM, Juurlink DN, et al. Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacol Res 2016;113:468-74. https://doi. org/10. 1016/j. phrs. 2016. 09. 027
4. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Aff (Millwood) 2002;21:245-53. https://doi. org/10. 1377/hlthaff. 21. 2. 245
5. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802. https://doi. org/10. 1056/NEJMoa1201735
6. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: A population-based cohort study. J Clin Oncol 2014;32:3177-83. https://doi. org/10. 1200/JCO. 2013. 54. 4569
7. Xu Y, Qi Y, Zhang J, et al. The impact of smoking on survival in renal cell carcinoma: A systematic review and meta-analysis. Tumour Biol 2014;35:6633-40. https://doi. org/10. 1007/s13277-014-1862-8
8. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of us adults. N Engl J Med 2003;348:1625-38. https://doi. org/10. 1056/ NEJMoa021423
9. Haddad AQ, Jiang L, Cadeddu JA, et al. Statin use and serum lipid levels are associated with survival outcomes after surgery for renal cell carcinoma. Urology 2015;86:1146-52. https://doi. org/10. 1016/j. urology. 2015. 09. 015
10. Hamilton RJ, Morilla D, Cabrera F, et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014;191:914-9. https://doi. org/10. 1016/j. juro. 2013. 10. 141
11. Kaffenberger SD, Lin-Tsai O, Stratton KL, et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol 2015;33:21. e11-7. https://doi. org/10. 1016/j. urolonc. 2014. 10. 007
12. Nayan M, Finelli A, Jewett M, et al. Statin use and kidney cancer survival outcomes: A propensity score analysis. Urol Oncol 2016;34:487. e1-6. https://doi. org/10. 1016/j. urolonc. 2016. 06. 007
13. Nayan M, Finelli A, Jewett MA, et al. Metformin use and kidney cancer outcomes in patients with diabetes: A propensity score analysis. Clin Genitourin Cancer 2016:30159-8.
14. Nayan M, Finelli A, Jewett MA, et al. Diabetes and kidney cancer outcomes: A propensity score analysis. Endocrine 2016;55:470-7. https://doi. org/10. 1007/s12020-016-1149-5
15. Austin PC, Stanbrook MB, Anderson GM, et al. Comparative ability of comorbidity classification methods for administrative data to predict outcomes in patients with chronic obstructive pulmonary disease. Ann Epidemiol 2012;22:881-7. https://doi. org/10. 1016/j. annepidem. 2012. 09. 011
16. Austin PC, van Walraven C. The mortality risk score and the ADG score: Two points-based scoring systems for the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care 2011;49:940. https://doi. org/10. 1097/ MLR. 0b013e318229360e
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83. https://doi. org/10. 1016/0021-9681(87)90171-8
18. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond. Stat Med 2008;27:157-72. https://doi. org/10. 1002/sim. 2929
19. Steyerberg EW, Pencina MJ. Reclassification calculations for persons with incomplete followup. Ann Intern Med 2010;152:195-6. https://doi. org/10. 7326/0003-4819-152-3-201002020-00019
20. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21. https://doi. org/10. 1002/sim. 4085
21. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: Extension to survival analysis. Stat Med 2011;30:22-38. https://doi. org/10. 1002/sim. 4026
22. Analyzing survival data with competing risks using SAS software. SAS Global Forum; 2012.
23. Kamat AM, Shock RP, Naya Y, et al. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumours. Urology 2004;63:46-50. https://doi. org/10. 1016/j. urology. 2003. 08. 009
24. Jeon HG, Jeong IG, Lee JH, et al. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol 2010;183:448-54. https://doi. org/10. 1016/j. juro. 2009. 10. 004
25. Schrader AJ, Rustemeier J, Rustemeier JC, et al. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol 2009;135:1693-9. https://doi. org/10. 1007/s00432-009-0616-2
26. Haferkamp A, Pritsch M, Bedke J, et al. The influence of body mass index on the long term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int 2008;101:1243-6. https://doi. org/10. 1111/j. 1464-410X. 2007. 07375. x
27. Donat SM, Salzhauer EW, Mitra N, et al. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J Urol 2006;175:46-52. https://doi. org/10. 1016/S0022-5347(05)00054-6
28. Parker AS, Lohse CM, Cheville JC, et al. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006;68:741-6. https://doi. org/10. 1016/j. urology. 2006. 05. 024
29. Sweeney C, Farrow DC. Differential survival related to smoking among patients with renal cell carcinoma. Epidemiology 2000;11:344-6. https://doi. org/10. 1097/00001648-200005000-00021
30. Richey SL, Culp SH, Jonasch E, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011;22:1048-53. https://doi. org/10. 1093/annonc/mdq563
31. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear-cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade, and necrosis: The SSIGN score. J Urol 2002;168:2395-400. https://doi. org/10. 1016/S0022-5347(05)64153-5
32. Han K-R, Bleumer I, Pantuck AJ, et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003;170:2221-4. https://doi. org/10. 1097/01. ju. 0000096049. 64863. a1
33. Karakiewicz PI, Briganti A, Chun FK-H, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007;25:1316-22. https://doi. org/10. 1200/JCO. 2006. 06. 1218